SIOC 中文
CJOG
Adv search

Chinese Journal of Organic Chemistry >

2013 , Vol. 33 >Issue 05: 1026 - 1034

DOI: https://doi.org/10.6023/cjoc201211052

Articles

Design, Synthesis, and Biological Evaluation of N-Aryl-salicylamide Derivatives as Potential Antitumor Agents

  • Wang Jie ,
  • Wu Hao ,
  • Li Jiaming ,
  • Xu Qinlong ,
  • He Guangwei ,
  • Zhong Guochen ,
  • Zhang Yanchun
Expand
  • a Anhui Key Laboratory of Traditional Chinese Medicine, Department of Pharmacy, Anhui College of Traditional Chinese Medicine, Hefei 230031;
    b Hefei Medical Engineering Pharmaceutical Co, Ltd., Hefei 230059

Received date: 2012-12-03

  Revised date: 2013-01-15

  Online published: 2013-01-21

Fold

Abstract

According to the scaffold hopping, a series of N-aryl-salicylamide derivatives, which have fragments of tyrosine kinase inhibitors lapatinib and neratinib were designed and synthesized. Their structures were identified by IR, 1H NMR, 13C NMR and MS techniques. The target compounds were tested for cytotoxic activity against four cancer cell lines, including A549, MCF-7, SGC-7901, Bel-7402, by methyl thiazolyl tetrazolium (MTT) in vitro. All the compounds demonstrated certain antitumor abilities, and some of them were better than gefitinib.

Key words： N-aryl-salicylamide; tyrosine kinase inhibitors; antitumor

Cite this article

Wang Jie , Wu Hao , Li Jiaming , Xu Qinlong , He Guangwei , Zhong Guochen , Zhang Yanchun . Design, Synthesis, and Biological Evaluation of N-Aryl-salicylamide Derivatives as Potential Antitumor Agents[J]. Chinese Journal of Organic Chemistry, 2013 , 33(05) : 1026 -1034 . DOI: 10.6023/cjoc201211052

References

[1] Zhao, X.; Guo, C.-B.; Zhou, H. Chin. J. Med. Chem. 2010, 20(5), 442 (in Chinese).
(赵欣, 郭长彬, 周化, 中国药物化学杂志, 2010, 20(5), 442.)
[2] Levitzki, A.; Klein, S. Mol. Aspects Med. 2010, 31(4), 287.
[3] Curigliano, G. Cancer Treat. Rev. 2012, 38(4), 303.
[4] Hoelder, S.; Clarke, P. A.; Workman, P. Mol. Oncol. 2012, 6(2), 155.
[5] Singh, J.; Petter, R. C.; Kluge, A. F. Curr. Opin. Chem. Biol. 2010, 14(4), 475.
[6] Dienstmann, R.; Dossob, S. D.; Felipa, E.; Taberneroa, J. Mol. Oncol. 2012, 15, 26.
[7] Kim, J. W.; Kim, H. P.; Kang, S.; Hur, H. S.; Yoon, Y. K.; Oh, D. Y.; Kim, J. H.; Lee, D. S.; Kim, T. Y.; Bang, Y. J. Cancer Lett. 2008, 272(2), 296.
[8] Slobbe, P.; Poot, A. J.; Windhorst, A. D.; Dongen, G. V. Drug Discovery Today 2012, 17(21-22), 1175.
[9] Dolezal, R.; Damme, S. V.; Bultinck, P.; Waisser, K. Eur. J. Med. Chem. 2009, 44(2), 869.
[10] Liechti, C.; Sequin, U.; Bold, G.; Furet, P.; Meyer, T.; Traxler, P. Eur. J. Med. Chem. 2004, 39(1), 11.
[11] Yang, Y.; Shi, L.; Zhou, Y.; Li, H.-Q.; Zhu, Z.-W.; Zhu, H.-L. Bioorg. Med. Chem. Lett. 2010, 20(22), 6653.
[12] Jin, Y.-L.; Lu, Z.-Z.; Ding, K.; Li, J.; Du, X.; Chen, C.; Sun, X.-Y.; Wu, Y.-B.; Zhou, J.; Pan, J.-X. Cancer Res. 2010, 70, 6 2516.
[13] Guo, L.; Wang, Q. L.; Jiang, Q. Q.; Jiang, Q. J.; Jiang, Y. B. J. Org. Chem. 2007, 72, 9947.
[14] Zhang, P.-X.; Mao, Y.-J.; Shen, J.-S.; Wei, Y.-B. Chin. J. Med. Chem. 2008, 18(5), 355 (in Chinese).
(张佩璇, 茆勇军, 沈敬山, 韦亚兵, 中国药物化学杂志, 2008, 18(5), 355.)
[15] Waissera, K.; Buresa, O.; Holya, P.; Kunesa, J.; Oswalda, R.; Jiraskova, L.; Poura, M.; Klimesova, V.; Kubicova, L.; Kaustovab, J. Arch. Pharm. Pharm. Med. Chem. 2003, 336(1), 53.
[16] Song, J.-P.; Zhong, P.; Wang, T.; Wei, X.-L.; Zhang, H. J. Cell Mol. Immunol. 2001, 17(3), 292 (in Chinese).
(宋锦平, 钟萍, 汪涛, 温秀兰, 张虹, 细胞与分子免疫学杂志, 2001, 17(3), 292.)
[17] Datki, Z.; Juhasz, A.; Galfi, M.; Soos, K.; Papp, R.; Zadori, D.; Penke, B. Brain Res. Bull. 2003, 62(3), 223.
Options
Outlines

/

〈 〉